Tan et al. (2013)Tan, Y., Zhang, T., Peng, J. J., & Zhao, Y. (2013). Short-term Efficacy and Safety of Recombinant Human Endostatin Combined with GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer. China Pharmacy, 24(36), 3416-3418.
|
IIIb~IV |
21 |
Gemcitabine(G) 1000 mg/m2, intravenous injection (ij), qd, d1-8+Cisplatin (C) 25 mg/m2, ij, qd, d1-3
|
The same chemotherapy as control group+ Endostar (E) 7.5 mg/m2 with 0.9% sodium chloride injection (SCI) 500 mL, intravenous injection (ij), qd, d1-14
|
38 |
38 |
61.7 ± 9.8 |
①②③④⑤ |
3 |
Xie & Huang (2009)Xie, Y. R., & Huang, J. J. (2009). Clinical study of Endostar combined GP regimen in the treatment of advanced non-small cell lung cancer. Chinese Journal of Gerontolog, 29(16), 2035-2037.
|
III~ IV |
21 |
G1000 mg/m2, d1 and d8+ C75 mg/m2, ij, qd, d1-3
|
The same chemotherapy as control group+E 15 mg with 0.9% SCI 500 mL, d1-14, ij |
26 |
22 |
56.5 |
59 |
①②③④⑤ |
2 |
Chen et al. (2010)Chen, Y. X., Cheng, H. N., & Chen, L. (2010). Efficacy of endostar combined with vinorelbine and cisplatin in treatment of advanced non-small-cell Lung cancer. Hainan Medical Journal, 21(18), 20-22.
|
IIIb~IV |
21 |
G 1000 mg/m2, ij, d1 and d8+C 25 mg/m2, ij, d1-3
|
The same chemotherapy as control group+E 15 mg with 0.9% SCI 500 mL, d1-14, ij |
25 |
30 |
49 ± 3 |
50 ± 2 |
①②③④⑤ |
1 |
Gu et al. (2010)Gu, Y., Lu, H. Y., & Jiang, A. G. (2010). Clinical study of recombinant human endostatin combined with GP regimen for advanced non-small cell lung cancer. Journal of Clinical Medicine in Practice, 14(9), 86-87.
|
IIIb~IV |
21 |
G 1000 mg/m2, d1 and d8+C 25 mg/m2, ij, d1-3
|
The same chemotherapy as control group+E 15 mg with 0.9% SCI 500 mL, d1-14, ij |
33 |
27 |
53.6 |
①②③④⑤ |
1 |
Guo (2010)Guo, H. B. (2010). Efficacy of endostar combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Chinese and Foreign Health Digest, 7(33), 120.
|
III~ IV |
21 |
G 1000 mg/m2, ij, d1 and d8+C 30 mg/m2, ij, d1-3
|
The same chemotherapy as control group+E15 mg, ij, d1-14
|
38 |
38 |
55 ± 12 |
53 ± 14 |
① ②④ |
2 |
Wei et al. (2010)Wei, Q. H., Ding, H. Z., & Tao, Y. J. (2010). Observation of treating advanced non- small cell lung cancer with recombinant human endostatin combined with GP. Journal of Clinical Medicine in Practice, 14(1), 36-38.
|
IIIb~IV |
21 |
G1g/m2, ij, d1 and d8+ C 30 mg/m2, ij, d2-4
|
The same chemotherapy as control group+E15 mg, qd, d1-14, ij |
16 |
16 |
59.8 |
①②③④⑤ |
2 |
Xu (2010)Xu, J. (2010). Evaluation of clinical efficacy of recombinant human endostatin combined with interventional therapy in non-small cell lung cancer. Guangzhou: China Southern Medical University.
|
IIIb~IV |
36 |
G1000 mg/m2 +C 30 mg/m2,Tumor target artery perfusion, d1; G1000 mg/m2, ij, d8+0.9% SCI 500 mL, ij, d2-12
|
G 1000 m g/m2+C 30 mg/m2,Tumor target artery perfusion, d1;G 1000 mg/m2, ij, d8,E 15 mg/d+0.9% SCI 500 mL, ij, d2-12
|
20 |
20 |
64 |
①②③④⑤ |
2 |
Chen et al. (2011)Chen, Q., Xie, Q., & Shi, Q. (2011). Short-term efficacy of YH-16 combined with GP regimen for advanced non-small cell lung cancer. Zhongliu Fangzhi Yanjiu, 38(2), 199-201.
|
III~ IV |
21 |
G1000 mg/m2, ij, d1、d8+C80 mg/m2, ij, d1
|
The same chemotherapy as control group+E 15 mg with 0.9% SCI 500 mL, d1-14, ij |
35 |
33 |
65 |
63 |
①②③④⑤ |
1 |
Ruan & Sun (2011)Ruan, M., & Sun, L. Y. (2011). Observation on the efficacy of recombinant human endostatin combined with GP regimen in the treatment of advanced non-small cell lung cancer. Chinese and Foreign Health Digest, 8(30), 54-55.
|
IIIb~IV |
21 |
G1000 mg/m2, d1 and d8+C75 mg/m2, ij, d1-3
|
The same chemotherapy as control group+E 15 mg with 0.9% SCI 500 mL, d1-14, ij |
19 |
17 |
58.5 |
①②③⑤ |
1 |
Wang (2011)Wang, F. (2011). Clinical study of endostar combined with GP regimen in the treatment of advanced non-small cell lung cancer. Medicina Infantil, 24(11), 118-119.
|
IIIb~IV |
21 |
G 1000 mg/m2, ij, d1 and d8+C 75 mg/m2, ij, d1
|
The same chemotherapy as control group+E 15 mg with 0.9% SCI500 mL, d1-14, ij |
29 |
31 |
55 |
56 |
① ② |
1 |
Zheng et al. (2011)Zheng, Q. P., Luo, Z. X., & Li, J. (2011). Clinical observation of endostatin combined with GP regimen in the treatment of stage IV non-small cell lung cancer. Guangxi Medical Journal, 33(5), 564-565.
|
IV |
21-28 |
G 1000 mg/m2, ij, d1 and d8+Cisplatin 20 mg/m2, intravenous injection, d1-5
|
The same chemotherapy as control group+Endostar 15 mg/d, d1-14
|
18 |
17 |
54.5 |
50.1 |
①②⑤ |
1 |
Chen & Yang (2012)Chen, B., & Yang, W. B. (2012). Observation of curative effect of recombinant human endostatin combined with GP regimen on non-small cell lung cancer. Journal of Clinical Pulmonary Medicine, 17(5), 869-870.
|
Not mentioned |
14 |
Gemcitabine 1000 mg/m2 wiht 0.9% Sodium chloride injection 100 mL, intravenous injection, d1 and d8+Cisplatin 25 mg/m2 with 0.9%Sodium chloride injection 500 mL, intravenous injection, d2-4
|
The same chemotherapy as control group+Endostar 15 mg, intravenous injection, qd, d1-14
|
26 |
27 |
56.5 ± 7.3 |
55.7 ± 8.6 |
①②③④⑤ |
1 |
He (2012)He, R. (2012). Analysis on efficacy of endostar combined with cisplatin chemotherapy in treatment of senile advanced non -small cell lung cancer. Practical Preventive Medicine, 19(8), 1230-1232.
|
III~ IV |
21 |
Gemcitabine 1000 mg/m2, d1 and d8+Cisplatin 30 mg/m2, d2-4
|
The same chemotherapy as control group+Endostar 7.5 mg/m2, d1-14
|
32 |
40 |
69.8 ± 5.5 |
70.5 ± 5.3 |
①②⑤ |
1 |
Liu et al. (2012)Liu, J. W., Geng, L., & Liu, Z. W. (2012). Efficacy of endo combined with GP chemotherapy in the treatment of non-small cell lung cancer. Monthly Psychiatrist, 17, 121-122.
|
IIIb~IV |
21 |
Gemcitabine 1000 mg/m2, intravenous injection, d1 and d8+Cisplatin 75 mg/m2, intravenous injection |
The same chemotherapy as control group+Endostar 15 mg, d1-7
|
30 |
30 |
56 |
58 |
①②③④⑤ |
2 |
Luan (2012)Luan, W. Q. (2012). Relationship between circulating endothelial progenitor cells and Endostar in non-small cell lung cancer. Zhengzhou: Zhengzhou Univerisity.
|
III~ IV |
21 |
Gemcitabine 1250 mg/m2, intravenous injection, d1 and d8+Cisplatin 75 mg/m2, intravenous injection, d1
|
The same chemotherapy as control group+Endostar 75 mg/m2 with 0.9% Sodium chloride injection 500 mL, d1-14, intravenous injection |
27 |
25 |
40-67 |
42-68 |
① ② |
1 |
Yin et al. (2012)Yin, F., Wu, L., & He, W. (2012). Clinical application of recombinant human endostatin combined with GP protocol in advanced non-small cell lung cancer. Journal of Clinical Pulmonary Medicine, 17(11), 2098-2099.
|
Not mentioned |
21 |
Gemcitabine 1000 mg/m2, intravenous injection, d1 and d8+Cisplatin 30 mg/m2, intravenous injection, d2-4
|
The same chemotherapy as control group+Endostar 15 mg with 0.9% Sodium chloride injection 500 mL, intravenous injection, qd, d1-14
|
90 |
94 |
49.3 ± 4.5 |
48.3 ± 5.2 |
①②⑤ |
1 |
Alimujiang et al. (2013)Alimujiang, S., Zhang, T., Patiguli, A., & Liu, L. (2013). Clinical analysis of recombinant human endostatin combined with gemcitabine and cisplatin therapy in advanced non-small cell lung cancer. Shandong Daxue Xuebao. Yixue Ban, 51(3), 95-98.
|
IIIb~IV |
21 |
Gemcitabine 1.0 g/m2 with 250 mL 0.9% Sodium chloride injection, d1 and d14, intravenous injection +Cisplatin with 500 mL 0.9% Sodium chloride injection, intravenous injection, d1-3
|
The same chemotherapy as control group+Endostar 15 mg with 0.9% Sodium chloride injection 500 mL, d1-14, intravenous injection |
40 |
40 |
59.2 ± 9.5 |
58.3 ± 9.6 |
①②③④⑤ |
2 |
Zhang (2014)Zhang, Y. Y. (2014). Clinical study of first-line treatment of advanced human squamous cell carcinoma with recombinant human endostatin (endostar) combined with chemotherapy (GP protocol). Hangzhou: Zhejiang University.
|
IIIb~IV |
21 |
Gemcitabine 1000 mg/m2, d1 and d8+Cisplatin 75 mg/m2, dosing in 3 days |
The same chemotherapy as control group+Endostar 15 mg with 0.9% Sodium chloride injection 250 mL, Intravenous pumping, d1-9
|
28 |
31 |
54 |
53 |
①②③④⑤ |
2 |
Fu et al. (2015)Fu, H., Yuan, C. P., & Xiao, C. J. (2015). Short term efficacy of Endostar combined with GP regimen in the treatment of advanced non-small cell lung cancer. Journal of Taishan Medical College, 36(12), 1367-1368.
|
IIIb~IV |
21 |
Gemcitabine 1000 mg/m2, intravenous injection, d1 and d8+Cisplatin 25 mg/m2, intravenous injection, d1-3
|
The same chemotherapy as control group+Endostar15 mg with 0.9% Sodium chloride injection 500 mL, d1-14, intravenous injection |
28 |
32 |
55.81 |
56.21 |
①②③④⑤ |
2 |
Liu (2015)Liu, T. (2015). Clinical efficacy of GP regimen combined with Endostar in the treatment of advanced non-small cell lung cancer. China Practical Medicine, 10(2), 43-44.
|
III~ IV |
21 |
Gemcitabine 1000 mg/m2, intravenous injection, d1 and d8+Cisplatin 80 mg/m2, intravenous injection, d1-2
|
The same chemotherapy as control group+Endostar 15 mg with 0.9% Sodium chloride injection 500 mL, d1-14
|
32 |
32 |
无 |
① ② |
2 |
Li et al. (2016)Li, L. H., Fu, Y. M., & Jin, Z. (2016). Investigation of gemcitabine combined with endostatin in the treatment of advanced non-small cell lung cancer. Jiangxi Medical Journal, 51(12), 1412-1414.
|
IIIb~IV |
21 |
Gemcitabine 1000 mg/m2, intravenous injection, d1 and d8+Cisplatin 30 mg/m2, intravenous injection, d1-3
|
The same chemotherapy as control group+Endostar 15 mg with 0.9% Sodium chloride injection 500 mL, d1-14, intravenous injection |
23 |
23 |
52.3 ± 10.6 |
①②③④⑤ |
3 |
Fang (2017)Fang, L. (2017). Clinical observation on efficacy of recombinant human endostatin combined with chemotherapy for advanced non-small cell lung cancer. Journal of Medical Forum, 38(8), 49-50.
|
Not mentioned |
21 |
Gemcitabine 1000 mg/m2, intravenous injection, d1 and d8+Cisplatin 75 mg/m2, intravenous injection,used 3 days continuously |
The same chemotherapy as control group+Endostar 7.5 mg/m2 with 0.9% Sodium chloride injection 500 mL, qd, d1-14
|
23 |
23 |
52 |
60 |
① ② |
2 |
Jia et al. (2017)Jia, X. Q., Sun, Q. Y., & Wen, Z. P. (2017). Clinical observation of recombinant human endostatin combined with gemcitabine and cisplatin therapy in advanced non-small cell lung cancer. Inner Mongolia Medical Journal, 49(1), 29-32.
|
IIIb~IV |
21 |
Gemcitabine 1.0 mg/m2 with 0.9% Sodium chloride injection 150 mL, intravenous injection, d1 and d8+Cisplatin 25 mg/m2 with 0.9% Sodium chloride injection 500 mL, intravenous injection, d1-3
|
The same chemotherapy as control group+Endostar 30 mgwith 0.9% Sodium chloride injection 110 mL, d1-7
|
20 |
20 |
50 ± 2 |
①②③④⑤ |
2 |
Xu & Wu (2017)Xu, L., & Wu, L. (2017). Clinical observation of recombinant human endostatin combined with GP chemotherapy for advanced non-small cell lung cancer. Chinese Journal of Clinical Rational Drug Use, 10(13), 91-92.
|
Not mentioned |
21 |
Gemcitabine 1.0 g/m2 wiht 0.9% Sodium chloride injection 250 mL, intravenous injection, d1 and d8+Cisplatin 30 mg/m2 with 0.9% Sodium chloride injection 500 mL, intravenous injection, d1-3
|
The same chemotherapy as control group+Endostar 15 mg with 0.9% Sodium chloride injection 500 mL, intravenous injection, d1-14
|
35 |
35 |
54.1 ± 11.3 |
①②③⑤ |
3 |
Song et al. (2018)Song, W. C., Bao, Y., & Qian, J. (2018). Study on clinical efficacy of endostar combined with gemcitabine and cisplatin in the treatment of advanced lung squamous cell carcinoma and effect on quality of life. The Practical Journal of Cancer, 33(1), 59-62.
|
III~ IV |
21 |
Gemcitabine 1250 mg/m2, intravenous injection, d1 and d8+Cisplatin 25 mg/m2, intravenous injection, d1-3
|
The same chemotherapy as control group+Endostar 15 mg/m2, d1-7, intravenous injection |
30 |
30 |
61.7 |
57.4 |
①②③④⑤ |
1 |
Wang (2018)Wang, Z. F. (2018). Effects of endo combined with first-line GP chemotherapy on survival time and quality of life in patients with advanced lung squamous cell carcinoma. Journal of Medical Theory and Practice, 31(2), 210-211.
|
IIIb~IV |
21 |
Gemcitabine 1000 mg/m2 with 0.9% Sodium chloride injection 100 mL, intravenous injection, d1 and d2 applied Cisplatin 75 mg/m2 with 0.9% Sodium chloride injection 500 mL, intravenous injection, dosing in 3 days |
The same chemotherapy as control group+Endostar 15 mg with 0.9% Sodium chloride injection 250 mL, intravenous pumping, d1-9
|
30 |
34 |
55.45 |
55.97 |
①②③④⑤ |
1 |
Zhong & Chen (2018)Zhong, L., & Chen, F. C. (2018). Efficacy and safety of Endostar combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Chinese Manipulation & Rehabilitation Medicine, 9(2), 66-67.
|
Not mentioned |
21 |
Gemcitabine 1000 mg/m2 with 0.9% Sodium chloride injection 150 mL, intravenous injection, d1 and d8 applied Cisplatin 30 mg/m2 with 0.9% Sodium chloride injection 500 mL, intravenous injection, d1-3
|
The same chemotherapy as control group+Endostar 7.5 mg/m2 with 0.9% Sodium chloride injection 100 mL, d1-14
|
25 |
25 |
70.34 |
70.21 |
①②③④⑤ |
2 |